Realm Therapeutics PLC Directorate Change (7718W)
November 17 2017 - 1:01AM
UK Regulatory
TIDMRLM
RNS Number : 7718W
Realm Therapeutics PLC
17 November 2017
Realm Therapeutics plc
("Realm Therapeutics", "Realm" or the "Company")
Realm Therapeutics Appoints Sandy Zweifach as Non-Executive
Director & Non-Executive Directors Matthew Hammond and Daniel
Hegglin Retire from the Board
17 November 2017 - Realm Therapeutics plc (AIM: RLM), a clinical
stage biopharmaceutical company focused on leveraging its
proprietary immunomodulatory technology, is pleased to announce
that Sanford (Sandy) Zweifach has been appointed to the Company's
board as a Non-Executive Director effective December 1, 2017.
Mr. Zweifach has over 25 years of experience in the life
sciences industry, with an extensive background in corporate
partnering, business development, operations, private and public
investing, and capital raising. He is Founder, President and Chief
Executive Officer (CEO) of Nuvelution Pharma, Inc., a company
facilitating the clinical advancement of late stage pharmaceutical
and biotechnology assets via a Research and Development
risk-sharing approach that deploys capital and human resources.
Prior to Nuvelution, Mr. Zweifach held executive leadership roles
in the biopharmaceutical industry and life sciences investment
banking, including: CEO of Ascendancy Healthcare, Inc.; Managing
Director of boutique investment bank Reedland Capital Partners; CEO
and President of biomarker development company Pathway Diagnostics
Corp.; Chief Financial Officer (CFO) and Managing Director of Bay
City Capital, a sector focused venture capital and merchant banking
firm; and President and CFO of Epoch Biosciences Corporation which
was subsequently acquired by Nanogen.
In addition to serving on the Board of Nuvelution, Mr. Zweifach
currently serves as Chairman of IMIDomics, focused on the discovery
and application of biomarkers and targets for immune-mediated
inflammatory diseases, and Chairman of Lyric Pharmaceuticals (a
company developing novel therapeutics to improve the care of
critically ill patients). He has served on Audit and Compensation
Committees. Mr. Zweifach holds a Masters of Science in Human
Physiology from the University of California (UC) Davis and a
Bachelor of Arts in Biology from UC San Diego and qualified as a
Certified Public Accountant with Coopers & Lybrand.
The Company further announces that current Non-Executive
Directors, Matthew Hammond and Daniel Hegglin, will retire from the
Board effective today, following the successful completion of the
Company's recent financing.
Charles Spicer, Non-Executive Chairman of Realm Therapeutics,
commented:
"The Board and I would like to thank Matthew and Danny for their
significant contributions to Realm during their tenure, including
guiding the transition of the Company to its current drug
development focus and the associated divestiture of non-core
businesses and repositioning of the business. We wish them both all
the best."
Alex Martin, Chief Executive Officer of Realm Therapeutics,
added:
"I am excited to welcome Sandy to the Board. His background and
experience in both the biopharmaceutical industry and investment
banking will be helpful as we progress our pipeline and expand our
optionality in 2018 and beyond. I would like to add my thanks to
Danny and Matthew for their support and guidance since I joined the
Company."
Additional disclosures as required by the AIM Rules for
Companies are included at the end of this announcement.
Contact:
Realm Therapeutics plc
Alex Martin, Chief Executive Officer
Marella Thorell, Chief Financial Officer and Chief Operating
Officer
+44 (0) 20 3727 1000
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
Argot Partners
Stephanie Marks
+1 212 600 1902
N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen
Boorer
+44 (0) 20 7496 3000
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company
focused on developing novel immunomodulatory therapies to protect
and improve the lives of adults and children. The Company has
initiated drug development programs, based on its proprietary
hypochlorous acid technology at high concentrations. The Company
believes its formulations have novel immunomodulatory activity with
potential application for the treatment of diseases in a number of
therapeutic areas, including Dermatology and Ophthalmology.
Additional disclosures:
The following information is disclosed pursuant to Schedule Two
paragraph (g) of the AIM Rules for Companies. Mr. Sanford Zweifach,
aged 61 years, has been a director of the following companies
during the five years preceding the date of this announcement.
Current directorships: Past Directorships:
------------------------ -------------------------
IMIDomics, Inc. Anthera Pharmaceuticals,
Inc.
------------------------ -------------------------
Nuvelution Pharma, Inc. Viventia Bio, Inc.
------------------------ -------------------------
Lyric Pharmaceuticals, Ascendancy Healthcare,
Inc. Inc.
------------------------ -------------------------
There is no further information to be disclosed pursuant to Rule
17 or Schedule Two paragraph (g) of the AIM Rules for
Companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADBBDBSDBBGRL
(END) Dow Jones Newswires
November 17, 2017 02:01 ET (07:01 GMT)
Realm Thera. (LSE:RLM)
Historical Stock Chart
From Apr 2024 to May 2024
Realm Thera. (LSE:RLM)
Historical Stock Chart
From May 2023 to May 2024